PMID- 33684244
OWN - NLM
STAT- MEDLINE
DCOM- 20220314
LR  - 20220531
IS  - 1525-139X (Electronic)
IS  - 0894-0959 (Linking)
VI  - 34
IP  - 6
DP  - 2021 Nov
TI  - Anticoagulation strategies in continuous renal replacement therapy.
PG  - 416-422
LID - 10.1111/sdi.12959 [doi]
AB  - The most common anticoagulant options for continuous renal replacement therapy 
      (CRRT) include unfractionated heparin (UFH), regional citrate anticoagulation 
      (RCA), and no anticoagulation. Less common anticoagulation options include UFH 
      with protamine reversal, low-molecular weight heparin (LMWH), thrombin 
      antagonists, and platelet inhibiting agents. The choice of anticoagulant for CRRT 
      should be determined by patient characteristics, local expertise, and ease of 
      monitoring. The Kidney Disease Improving Global Outcomes (KDIGO) acute kidney 
      injury guidelines recommend using RCA rather than UFH in patients who do not have 
      contraindications to citrate and are with or without increased risk of bleeding. 
      Monitoring should include evaluation of the anticoagulant effect, circuit life, 
      filter efficacy, and complications.
CI  - (c) 2021 Wiley Periodicals LLC.
FAU - Legrand, Matthieu
AU  - Legrand M
AUID- ORCID: 0000-0001-9788-5316
AD  - Department of Anesthesia and Perioperative Care, Division of Critical Care 
      Medicine, UCSF School of Medicine, San Francisco, CA, USA.
AD  - INI-CRCT Network, Nancy, France.
FAU - Tolwani, Ashita
AU  - Tolwani A
AD  - Department of Internal Medicine, Division of Nephrology, University of Alabama at 
      Birmingham, Birmingham, AL, USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20210308
PL  - United States
TA  - Semin Dial
JT  - Seminars in dialysis
JID - 8911629
RN  - 0 (Anticoagulants)
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - 9005-49-6 (Heparin)
SB  - IM
MH  - *Acute Kidney Injury/therapy
MH  - *Anticoagulants/therapeutic use
MH  - *Continuous Renal Replacement Therapy
MH  - *Heparin/therapeutic use
MH  - Heparin, Low-Molecular-Weight/therapeutic use
MH  - Humans
MH  - Renal Dialysis
MH  - *Renal Replacement Therapy
OTO - NOTNLM
OT  - anticoagulation
OT  - citrate
OT  - continuous renal replacement therapy
EDAT- 2021/03/09 06:00
MHDA- 2022/03/15 06:00
CRDT- 2021/03/08 17:10
PHST- 2021/01/21 00:00 [revised]
PHST- 2020/12/23 00:00 [received]
PHST- 2021/01/23 00:00 [accepted]
PHST- 2021/03/09 06:00 [pubmed]
PHST- 2022/03/15 06:00 [medline]
PHST- 2021/03/08 17:10 [entrez]
AID - 10.1111/sdi.12959 [doi]
PST - ppublish
SO  - Semin Dial. 2021 Nov;34(6):416-422. doi: 10.1111/sdi.12959. Epub 2021 Mar 8.